Podoplanin expression in malignant ovarian cancer;Ekspresja genu podoplaniny w złośliwych nowotworach jajnika

Przeglad Menopauzalny

Volumn 15, Issue 2, 2011, Pages 102-105

  Marzec Kotarska, Barbara ^a   Kotarski, Józef ^b   Cybulski, Marek ^c   Antosz, Halina ^a   Kocki, Janusz ^a   Bednarek, Wiesława ^b  

^a Samodzielna Pracownia Genetyki Klinicznej Uniwersytetu Medycznego W Lublinie   (Poland)

^b I Katedra i Klinika Ginekologii Onkologicznej i Ginekologii Uniwersytetu Medycznego w Lublinie   (Poland)

^c Katedra I Zakład Biochemii I Biologii Molekularnej ^*  (Poland)

Author keywords

Ovarian cancer; Podoplanin

Indexed keywords

MESSENGER RNA; PODOPLANIN;

ADENOCARCINOMA; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; OVARY CANCER; OVARY MUCINOUS ADENOCARCINOMA; OVARY SEROUS ADENOCARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 79955439366     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2006; 20: 207-25.
2. Pectasides D, Fountzilas G, Aravantinos G, et al. Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer 2007; 17: 1003-10.
3. Vo C, Carney ME. Ovarian cancer hormonal and environmental risk effect. Obstet Gynecol Clin North Am 2007; 34: 687-700.
4. Nagahashi M, Ramachandran S, Rashid OM, Takabe K. Lympha ngiogenesis: a new player in cancer progression. World J Gastroenterol 2010; 16: 4003-12.
5. Raica M, Cimpean AM, Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res 2008; 28: 2997-3006.
6. Yu H, Gibson JA, Pinkus GS, Hornick JL. Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Am J Clin Pathol 2007; 128: 776-82.
7. Müller AM, Franke FE, Müller KM. D2-40: a reliable marker in the diagnosis of pleural mesothelioma. Pathobiology 2006; 73: 50-4.
8. Kato Y, Kaneko M, Sata M, et al. Enhanced expression of Aggrus (T1alpha/ podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 2005; 26: 195-200.
9. Dumoff KL, Chu CS, Harris EE, et al. Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Mod Pathol 2006; 19: 708-16.
10. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005; 166: 913-21.
11. Oe S, Hasegawa K, Nagase S, et al. Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma. Int J Gynecol Pathol 2010; 29: 405-10.
12. Kawamura L, Carvalho FM, Alves BG, et al. Association between intratumoral lymphatic microvessel density (LMVD) and clinicopathologic features in endometrial cancer: a retrospective cohort study. World J Surg Oncol 2010; 8: 89.
13. Ito T, Ishii G, Nagai K, et al. Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer 2009; 63: 418-24.
14. Suzuki H, Onimaru M, Koga T, et al. High podoplanin expression in cancer cells predicts lower incidence of nodal metastasis in patients with lung squamous cell carcinoma. Pathol Res Pract 2011; 207: 111-5.
15. Sundar SS, Zhang H, Brown P, et al. Role of lymphangiogenesis in epithelial ovarian cancer. Br J Cancer 2006; 94: 1650-7.